CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

49.39 -0.60 (-1.20%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Price and Volume

Volume	2,120,034
Open	49.31
Bid (Size)	49.00 (100)
Ask (Size)	49.60 (3,400)
Prev. Close	49.99
Today's Range	48.02 - 49.68
52wk Range	44.12 - 68.71
Shares Outstanding	78,935,098
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Where Will CRISPR Therapeutics Stock Be in 2030? ↗

October 18, 2026

The company's expertise in gene editing could lead to more breakthroughs.

Via The Motley Fool

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. ↗

October 18, 2026

Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.

Via The Motley Fool

Performance

52-Week Range 28.1% below 52-week high

49.39

44.1252W Low 68.7152W High

1 Week 3.3% below 1-week high

47.361W Low 51.051W High

CRISPR Therapeutics AG - Common Shares (CRSP) traded between $44.12 and $68.71 over the past 52 weeks and last traded at $49.39, 28.1% below its 52-week high. Over the past week it ranged between $47.36 and $51.05.

Past 12 Months

-1.3%

-11.4%

+6.1%

+1.2%

-8.1%

-26.5%

1W -$0.65

1M -$6.37

3M +$2.85

6M +$0.61

YTD -$4.38

1Y -$17.82

CRSP was -26.5% over the past year, +1.2% over six months, -8.1% year to date, -1.3% in the last week.

12 Months vs Market

CRSP

-26.5%

DIA

+11.6%

SPY

+13.1%

QQQ

+15.4%

IWM

+11.9%

Over the past 12 months CRSP returned -26.5% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 1.36× 3-mo avg

Today 2,120,034 3-mo avg 1.6M

1.5M

1.6M

1.7M

YTD

1.7M

1.8M

CRSP most recently traded 2,120,034 shares against a 3-month average daily volume of 1.6M.

More News

Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. ↗

October 09, 2026

Via The Motley Fool

CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? ↗

September 29, 2026

Via The Motley Fool

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

Via The Motley Fool

3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 ↗

September 20, 2026

Via The Motley Fool

Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗

September 17, 2026

Via The Motley Fool

CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts ↗

September 14, 2026

Via MarketBeat

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 14, 2026

Via The Motley Fool

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 11, 2026

Via The Motley Fool

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 11, 2026

Via The Motley Fool

Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September ↗

September 11, 2026

Via The Motley Fool

Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗

September 08, 2026

Via The Motley Fool

Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗

September 08, 2026

Via The Motley Fool

2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗

September 02, 2026

Via The Motley Fool

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗

August 21, 2026

Via The Motley Fool

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗

August 20, 2026

Via The Motley Fool

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗

July 30, 2026

Via The Motley Fool

3 Stocks With the Most Upside by the End of 2026 ↗

July 30, 2026

Via The Motley Fool

3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside ↗

July 28, 2026

Via The Motley Fool

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating ↗

July 22, 2026

Via The Motley Fool

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗

July 20, 2026

Via The Motley Fool

3 Reasons to Buy CRISPR Therapeutics Stock ↗

July 10, 2026

Via The Motley Fool

Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗

July 08, 2026

Via MarketBeat

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗

July 08, 2026

Via The Motley Fool

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?

Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.

What exchange does CRISPR Therapeutics AG - Common Shares trade on?

CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?

The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market

What is the current price of CRISPR Therapeutics AG - Common Shares?

The current price of CRISPR Therapeutics AG - Common Shares is 49.39

When was CRISPR Therapeutics AG - Common Shares last traded?

The last trade of CRISPR Therapeutics AG - Common Shares was at 10/23/26 04:00 PM ET

What is the market capitalization of CRISPR Therapeutics AG - Common Shares?

The market capitalization of CRISPR Therapeutics AG - Common Shares is 3.90B

How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?

CRISPR Therapeutics AG - Common Shares has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.